NAV
$211.34
AUM
$366.9M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.58
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +11.67% | +12.41% | +13.25% | +35.75% | +11.33% | +1.29% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | 14.09% |
| 2 | AMGN | Amgen Inc | 13.90% |
| 3 | VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| 4 | ARGX | argenx SE ADR | 6.03% |
| 5 | REGN | Regeneron Pharmaceuticals Inc | 5.97% |
| 6 | RVMD | Revolution Medicines Inc Ordinary Shares | 4.63% |
| 7 | IQV | IQVIA Holdings Inc | 4.59% |
| 8 | NTRA | Natera Inc | 4.44% |
| 9 | BIIB | Biogen Inc | 3.97% |
| 10 | ALNY | Alnylam Pharmaceuticals Inc | 3.74% |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Inception Date: 2011-12-20